Editorial label review
Alloy side effects: fatigue
Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms
Quick answer
Fatigue shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.
What Alloy prescribes and why it matters for fatigue
Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. Fatigue / somnolence entries appear across estradiol, progesterone, and paroxetine PILs used by these brands.
Common label-level side effects
Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.
- Asthenia (fatigue) is listed at 3–7% in most estradiol combination PILs Section 6 adverse-reaction tables
- Prometrium PIL Section 6.1 lists somnolence at 8% — commonly reported as fatigue
- Brisdelle (paroxetine 7.5 mg) PIL lists fatigue at 5–8% in Section 6
Serious label-level warnings
Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.
- Fatigue paired with yellowing skin or dark urine — hepatic adverse-event signal on the estradiol and Prometrium labels
- Fatigue with chest pain or breathlessness — the estradiol PIL boxed warning covers cardiovascular events
When to contact your clinician
Contact your clinician if fatigue is sudden, paired with chest symptoms, or accompanied by jaundice — both estradiol and progesterone labels flag these as urgent.
Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.
What to ask your provider
- “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for fatigue?”
- “Is my fatiguelikely a labelled adverse reaction, or something separate that needs its own workup?”
- “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
- “What is the plan if fatiguedoes not settle within 2–3 cycles?”
Related editorial reading
- Full editorial review of Alloy — formulary, pricing, and clinician model.
- Is fatigue caused by menopause itself? — how the transition presents on its own.
- Estradiol medication page — mechanism, dosing, and full PIL notes.
- Progesterone medication page — secondary ingredient in Alloy's formulary.
- Browse all side-effect matrix pages — 4 brands × 15 symptoms.
Frequently asked questions
- How often does fatigue happen on Alloy?
- Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for fatigue described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
- When should I stop Alloy because of fatigue?
- Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
- Is fatigue on the FDA label for Alloy's medications?
- Fatigue / somnolence entries appear across estradiol, progesterone, and paroxetine PILs used by these brands.
- Is fatigue caused by menopause itself?
- Fatigue can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/fatigue explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.